Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

Bionano Genomics Partners with Revvity to Advance Newborn Sequencing Research through Software Marketing Agreement

NextEdge Admin

21 Jun 2024

2 min 53 sec

screening,software,Next Generation Sequencing,optical genome mapping

Bionano Genomics, Inc. has announced a strategic software marketing agreement with Revvity, Inc. aimed at enhancing newborn sequencing research capabilities. Under this agreement, Revvity will integrate and market Bionano’s VIA™ software into their sequencing workflow. The VIA software is expected to augment Revvity’s current capabilities by facilitating the assessment of Copy Number Variations (CNVs) and improving the interpretation of sequencing data.

The collaboration leverages Revvity’s comprehensive sequencing workflow, which includes various stages from DNA extraction of dried blood spot samples, through sample quality control, automated library preparation, sequencing using platforms like Element Biosciences or Illumina, to a hybridization-based NGS panel for detecting variants in over 390 relevant genes. This process is complemented by cloud-based data management and analysis powered by Bionano’s VIA software.

Dr. Erik Holmlin, President and CEO of Bionano, emphasized the transformative potential of the VIA software in visualizing, interpreting, and reporting genomic data. He highlighted its dual role in optical genome mapping (OGM) and Next Generation Sequencing (NGS) applications, underscoring Bionano’s commitment to advancing genomic insights across research and clinical domains, particularly in newborn sequencing research.

Bionano Genomics specializes in genome analysis solutions designed to address complex biological and medical questions. Their optical genome mapping technology and VIA software are pivotal in their mission to redefine genomic understanding. Additionally, the company offers platform-agnostic genome analysis software and proprietary nucleic acid extraction solutions through its isotachophoresis (ITP) technology. They also provide diagnostic services under their Lineagen, Inc. division, utilizing OGM for diagnostic testing.

The partnership with Revvity signifies Bionano’s strategic expansion into newborn sequencing research, facilitating the adoption of advanced NGS solutions globally. By integrating VIA software into Revvity’s workflow, both companies aim to streamline and enhance genomic analysis processes, potentially accelerating discoveries and clinical applications in genetics.